Strategies to achieve robustness in clinical proteomics research

Associate Professor Michelle Hill obtained her PhD at the University of Queensland, Brisbane, Australia, then under took postdoctoral research in Switzerland, Ireland, and back at University of Queensland. Her research training focussed on various aspects of cell signalling and membrane microdomain function using techniques in biochemistry, cell biology and subcellular proteomics. With a passion for translational medical research, Michelle established the Cancer Proteomics Group at the University of Queensland Diamantina Institute on the Princess Alexandra Hospital campus, Brisbane, Australia in 2009. Through interdisciplinary collaborations, her team implemented a mass spectrometry-based amyloidosis typing diagnostic test, which continues to benefit patients in the Australasia region.
In April 2017, Michelle's research began a new chapter at the QIMR Berghofer Medical Research Institute, Brisbane, Australia, where she also directs the Metabolomics Core Facility. The Precision and Systems Biomedicine Laboratory has been focusing on obesity-associated cancers, with specific projects on translating blood glycoprotein biomarkers for oesophageal adenocarcinoma, understanding lipid-driven mechanisms in cancers focussing on membrane microdomains and extracellular vesicles. The team also collaborates with other researchers on biomarker discovery and development of targeted mass spectrometry tests.